QLife (QLIFE) Q3 2024 earnings summary

Executive summary

• Q3 2024 saw no revenue, with EBITDA at KSEK -27,151 and a net loss of KSEK -28,087, reflecting a challenging period as the company transitions to commercialization of its Egoo Health platform.

• Major restructuring reduced the burn rate below SEK 0.5 million/month, and the company is now highly agile with a small team and support from a Chinese partner.

• The Egoo Phe test for PKU was launched as research-use-only, with initial shipments to seven countries and a total addressable market estimated at SEK 2.5 billion.

• Production of Egoo consumables is now established in China, supporting clinical trials and future sales, with a strategic focus on the Chinese home-hospital market.

Financial highlights

• Revenue for Q3 2024 was KSEK 0, down from KSEK 45 in Q3 2023; year-to-date revenue is KSEK 39 versus KSEK 214 last year.

• EBITDA for Q3 2024 was KSEK -27,151, compared to KSEK -6,660 in Q3 2023; net loss widened to KSEK -28,087 from KSEK -8,926.

• Cash flow in Q3 2024 was positive at KSEK 2,979, reversing a negative KSEK -3,631 in Q3 2023; cash reserves at period end were KSEK 3,066.

• Shareholders' equity at September 30, 2024, was KSEK 199, a significant drop from KSEK 91,504 a year earlier.

• Number of employees reduced to 3 from 13 in Q3 2023, reflecting restructuring.

Outlook and guidance

• Focus remains on gathering user feedback from the PKU segment and preparing for regulatory filings in the UK/EU and US.

• Expectation for partner Hipro to launch Egoo Health in China in 2025, with anticipated significant impact.

• Strategic partnerships and expansion into the home-hospital market outside China are ongoing priorities.